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Obesity and associated chronic inflammation initiate a state of insulin resistance (IR). The
secretion of chemoattractants such as MCP-1 and MIF and of cytokines IL-6,TNF-α, and IL-
1β, draw immune cells including dendritic cells, T cells, and macrophages into adipose
tissue (AT). Dysfunctional AT lipid metabolism leads to increased circulating free fatty
acids, initiating inflammatory signaling cascades in the population of infiltrating cells. A
feedback loop of pro-inflammatory cytokines exacerbates this pathological state, driving
further immune cell infiltration and cytokine secretion and disrupts the insulin signal-
ing cascade. Disruption of normal AT function is causative of defects in hepatic and
skeletal muscle glucose homeostasis, resulting in systemic IR and ultimately the devel-
opment of type 2 diabetes. Pharmaceutical strategies that target the inflammatory milieu
may have some potential; however there are a number of safety concerns surrounding
such pharmaceutical approaches. Nutritional anti-inflammatory interventions could offer
a more suitable long-term alternative; whilst they may be less potent than some phar-
maceutical anti-inflammatory agents, this may be advantageous for long-term therapy.
This review will investigate obese AT biology, initiation of the inflammatory, and insulin
resistant environment; and the mechanisms through which dietary anti-inflammatory
components/functional nutrients may be beneficial.
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INTRODUCTION
The global increase in body mass is an escalating societal con-
cern. Concomitant environmental factors such as poor dietary
habits, sedentary lifestyle, socioeconomic influences; and less fre-
quently, genetic disorders that impact on hormone secretion and
metabolism, result in weight gain. The world health organization
Abbreviations: AA, arachidonic acid; ACC, acetyl-CoA carboxylase; AKT, pro-
tein kinase B; AMPK, adenosine monophosphate activated protein kinase; AP-1,
activator protein-1; APC, antigen presenting cell; ASC, adipocyte stem cells; ASC,
apoptotic speck-like protein containing a CARD; ASO, antisense oligonucleotide;
AT, adipose tissue; ATM, adipose tissue macrophage; ATP, adenosine triphosphate;
BAT, brown adipose tissue; bFGF, basic fibroblast growth factor; BMDC, bone
marrow derived dendritic cell; BMI, body mass index; C/EBP, CCAAT/enhancer
binding protein; C3, complement component 3; CLA, conjugated linoleic acid;
CLS, crown-like structures; COX, cyclooxygenase; CVD, cardiovascular disease;
DAG, diacylglycerol; DC, dendritic cell; DHA, docosahexaenoic acid; DPP, dipep-
tidyl peptidase; EGCG, epigallocatechin gallate; EPA, eicosapentaenoic acid; ERK,
extracellular signal-regulated kinase; FA, fatty acid; FFA, free fatty acid; G6P, glu-
cose 6-phosphatase; GLP, glucagon-like peptide; GLUT, glucose transporter; GPCR,
G protein-coupled receptor; HDL, high-density lipoprotein; HFD, high-fat diet;
HIF, hypoxia-inducible factor; HMW, high-molecular weight; HSD1, hydroxys-
teroid dehydrogenase type 1; IFN, interferon; IGT, impaired glucose tolerance; IκB,
inhibitor of NF-κB; IKK, IκB kinase; IL, interleukin; iNKT, invariant natural killer
cell; iNOS, inducible nitric oxide synthase; IR, insulin resistance; IRAK, interleukin-1
receptor-associated kinase-1; IRS, insulin receptor substrate; IκB, inhibitor of NF-
κB kinase complex; JAK, janus kinase; JNK, Jun N-terminal kinase; KC, Kupffer
cell; LC, long chain; LDL, low-density lipoprotein; LMW, low molecularweight; LPS,
(WHO) projects that by 2015, 2.3 billion adults will be overweight,
body mass index (BMI) >25 (kg/m2) and more than 700 million
will be obese BMI >30 (kg/m2). Consequently obesity-related
co-morbidities including type 2 diabetes (T2D), cardiovascular
disease (CVD), and non-alcoholic fatty liver disease (NAFLD) will
continue to escalate (Kopelman, 2000; Mokdad et al., 2003).
lipopolysaccharide; MAPK, mitogen activated protein kinase; MCP, macrophage
chemoattractant protein; MDMs monocyte derived macrophages; MetS, meta-
bolic syndrome; MHO, metabolically healthy obese; MIF, macrophage migration
inhibitory factor; MMW, middle-molecular weight; MnSOD, mitochondrial dis-
mutase; MONW, metabolically obese normal weight; mTOR, mammalian target
of rapamycin; MYD88, myeloid differentiation primary response gene 88; NAFLD,
non-alcoholic fatty liver disease; NK, natural killer cell; NLRP3, NOD, like receptor
3; NO, nitric oxide; O2•− superoxide; PI, phosphatidylinositol; PI3K, phosphatidyli-
nositide 3-kinase; PKC, protein kinase C; PLC, phospholipase; PPAR, peroxisome
proliferator-activated receptor; Pref-1, Pre-adipocyte factor-1; PRR, pattern recog-
nition receptor; PUFA, polyunsaturated fatty acid; RA, receptor antagonist; ROS,
reactive oxygen species; SAT, subcutaneous adipose tissue; SFA, saturated fatty acid;
SGBS, Simpson–Gibson–Behmel syndrome; SHP2, protein tyrosine phosphatase,
non-receptor type 11; SIRT1, sirtuin1; SNP, single nucleotide polymorphism; SOCS,
suppressor of cytokine signaling; SREBP, sterol receptor binding protein; STAT,
signal-transducer and activator of transcription protein; SVF, stroma-vascular frac-
tion; T2D, type 2 diabetes; TAG, triacylglyceride; TAK, transforming growth factor
β activated kinase; TH, T helper cell; TLR, toll like receptor; TNF, tumor-necrosis
factor; TRADD, TNF receptor death domain; TRAF, TNF receptor-associated fac-
tor; Treg, regulatory T cell; VAT, visceral adipose tissue; WAT, white adipose tissue;
WHO, world health organization; WT, wild type.
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FIGURE 1 | Metabolic tissues implicated in obesity-induced
insulin resistance. Adipose tissue, liver, and skeletal muscle are
involved in glucose uptake, glucose production, and glucose
processing. These tissues therefore are paramount in obesity and
the progression of insulin resistance. A combination of defective
fatty acid storage and metabolism together with immune cell
infiltration and a pro-inflammatory tissue milieu result in
dysregulation of insulin signaling.
Substantial evidence indicates that obesity is linked to a
state of chronic low-grade inflammation. Initially Hotamisligil
et al. (1993) determined a link between obesity and inflamma-
tion; demonstrating that the pro-inflammatory cytokine tumor-
necrosis factor (TNF)-α was expressed in adipose tissue (AT)
of obese mice and linked to insulin resistance (IR). Significant
advances in understanding the highly complex role of immuno-
metabolism in health have since been accomplished. Consequently
obesity is linked to pro-inflammatory cytokine secretion, immune
cell infiltration, and disrupted function of tissues involved in glu-
cose homeostasis, summarized in Figure 1. Dysfunctional lipid
metabolism accompanies obesity and can impair insulin signaling;
circulating free fatty acids (FFAs) have a negative effect on insulin
target tissues, through the activation of inflammatory pathways,
via cell surface pattern recognition receptors (PRRs) (Shi et al.,
2006). Furthermore, accumulation of lipid derivatives, such as dia-
cylglycerol (DAG) and ceramides can negatively regulate insulin
action (Schenk et al., 2008).
The purpose of this review is to evaluate the current evidence
in relation to obesity-induced IR, whereby the inflammatory axis
plays a critical role in the progression and severity of IR. It is
possible to attenuate the pro-inflammatory, insulin de-sensitizing
milieu within the obesogenic environment. Weight management
programs can attenuate T2D risk by reducing obesity and improv-
ing insulin sensitivity; however the long-term success of this
approach is not optimal. Thus, are there effective nutritional
strategies to attenuate the impact of inflammation mediated IR
beyond weight loss?
ADIPOSE TISSUE, OBESITY-INDUCED INFLAMMATION, AND
INSULIN RESISTANCE
There are two distinct forms of AT, brown adipose tissue (BAT)
and white adipose tissue (WAT). BAT is typically associated with
thermogenesis, although initially thought to disappear soon after
birth in humans, evidence now suggests that BAT is present in adult
humans in the supraclavical and paraspinal regions (Yoneshiro
et al., 2011). Recent studies support the role of BAT functional-
ity in adult humans relating to the control of body temperature
and adiposity, which is of direct relevance to the metabolic syn-
drome (MetS) (Jacene et al., 2011; Ouellet et al., 2011; Nishio et al.,
2012). BAT levels and activity are inversely correlated with BMI
and conversely loss of BAT activity may be associated with the
accumulation of WAT (Saito et al., 2009; Van Marken Lichtenbelt
et al., 2009; Vijgen et al., 2011).
The depot most important to obesity and IR is WAT. WAT tradi-
tionally functions in lipid storage, storing triacylglycerides (TAG)
following energy excess,and mobilizing these stores during periods
of nutrient deprivation (Gregoire et al., 1998). With obesity and
IR there is increased lipolysis, consequently there is an inappro-
priate spill over of TAG derived FFAs (Sethi and Vidal-Puig, 2007)
and these FFAs can activate inflammatory pathways and impair
insulin signaling. WAT also acts as an endocrine organ, releas-
ing bioactive substances that have been coined adipokines, these
include interleukin (IL)-6, IL-1β, TNF-α, leptin, and adiponectin.
WAT is a complex multi-cellular organ, composed primarily of
adipocytes. The stroma-vascular fraction (SVF) of AT contains
several highly potent cells including adipocyte progenitor cells, or
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FIGURE 2 | Obese adipose tissue expansion – resultant
inflammation and metabolic dysregulation. Excess energy leads to
adipose expansion with hypertrophic adipocytes that secrete
chemoattractants such as MCP-1, drawing immune cells into the
tissue. Secretion of pro-inflammatory mediators such as TNF-α, IL-1β,
and IL-6 by adipocytes, pre-adipocytes, and infiltrating immune cells
results in polarization of macrophages to a pro-inflammatory M1
phenotype, and drive an inflammatory T cell population. Augmented
lipolysis leads to increased levels of FFAs. This environment negatively
impacts on the insulin signaling pathway and a state of insulin
resistance results. Additionally hypertrophic adipocytes are also linked
with hypoxia.
pre-adipocytes, and resident immune cell populations. In the IR
state, pro-inflammatory cytokines activate several serine kinases,
including IκB kinase (IKK) and JNK (Gual et al., 2005). These
kinases have been shown to inhibit insulin action by promoting
the phosphorylation of serine residues of the insulin signaling
pathway, including serine phosphorylation of insulin receptor
substrate-1 (IRS-1). In contrast with tyrosine phosphorylation of
IRS-1 in the insulin sensitive state, serine phosphorylation impairs
normal insulin signaling (Schenk et al., 2008).
ADIPOCYTES
White adipose tissue is unique in its plasticity, it can adapt quickly
to nutrient deprivation and hyper-nutrition alike. The flexibil-
ity of WAT is largely due to the hypertrophic and hyperplastic
changes in adipocytes. WAT plasticity has an important role in
determining metabolic health (Virtue and Vidal-Puig, 2008). The
expansion of WAT that occurs with weight gain is accompanied
by changes in cytokine and chemokine secretion, hypoxia, cell
death, immune cell infiltration, and dysregulation of fatty acid
(FA) metabolism and storage, see Figure 2. Adipocyte hyper-
trophy modulates the adipose secretome (Osborn and Olefsky,
2012). Mature adipocytes secrete IL-6, monocyte chemoattractant
protein (MCP)-1, leptin, and adiponectin; which can act in an
autocrine, paracrine, or endocrine manner to regulate lipid and
glucose homeostasis (Curat et al., 2004). Expression of inducible
nitric oxide synthase (iNOS), MCP-1 and IL-6 are concomitantly
increased in the mature adipocyte fraction of obese mice, in
parallel with increased 11β-hydroxysteroid dehydrogenase type
I (HSD1) levels (Ishii-Yonemoto et al., 2010). In in vitro cul-
tures TNF-α, IL-1β, and IL-6 up-regulate 11β-HSD1 (Tomlinson
et al., 2001). Increased MCP-1 expression promotes monocyte
infiltration of the WAT, these then differentiate into adipose tissue
macrophages (ATM). Adipocytes also induce the expression of the
adhesion molecules ICAM-1 and PECAM-1 on endothelial cells
(Curat et al., 2004) which further attract monocytes to the region.
ATM secrete additional chemokines and cytokines, further exacer-
bating the pro-inflammatory environment (Osborn and Olefsky,
2012).
STROMA-VASCULAR FRACTION
The SVF of WAT is composed of several metabolically active
and inflammatory cells, summarized in Figure 3; including pre-
adipocytes, fibroblasts, endothelial cells, dendritic cells (DCs), T
cells, mast cells, granulocytes, and macrophages (Calder et al.,
2011) embedded in an extra cellular matrix. This fraction plays
a critical role in healthy fat pad expansion (Sun et al., 2011). In
response to a high-fat diet (HFD) and obesity, there is an increase
in SVF cell number, the phenotype of which adversely affects
metabolism (Strissel et al., 2010).
PRE-ADIPOCYTES
Two distinct adipocyte cell types were identified in human omen-
tal fat (Julien et al., 1989). Mature adipocytes with lipid droplets
were observed in close proximity to much smaller nucleated cells
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FIGURE 3 | Major cell types involved in obesity-induced inflammation and insulin resistance; adipocytes, pre-adipocytes, dendritic cells,T cells, and
macrophages.
containing less lipid, referred to as pre-adipocytes. Increasing body
weight is associated with increased numbers of pre-adipocytes and
it has been suggested that the expansion of this cellular population
is associated with IR (McLaughlin et al., 2007). There is much spec-
ulation as to the origins of pre-adipocytes (Cawthorn et al., 2012).
Hollenberg andVost (1969) utilized tritiated thymidine incorpora-
tion in WAT and identified the SVF as the source of new adipocyte
formation. Adipocyte stem cells (ASCs) are likely mesenchymal
stem cells that reside in the WAT and give rise to adipocytes; with
pre-adipocytes representing an intermediary stage in this process
(Zuk et al., 2001; Cawthorn et al., 2012).
Cytokines have potent effects on pre-adipocyte biology. TNF-
α, interferon (IFN)-γ, IL-1β, and IL-6 impair adipogenesis and
lipid accumulation in 3T3-L1 pre-adipocytes (Gustafson and
Smith,2006; McGillicuddy et al., 2009). Specifically, IL-6 treatment
reduced adiponectin, resistin, glucose transporter type (GLUT)-4,
and IRS-1 expression; while TNF-α treatment increased secretion
of IL-6 and MCP-1 from pre-adipocytes (Chung et al., 2006).
Indeed pre-adipocytes secrete greater levels of pro-inflammatory
mediators such as IL-6 and MCP-1 than adipocytes (Poulain-
Godefroy and Froguel, 2007; Mack et al., 2009). Phospholipase Cδ1
(PLCδ1) has also been shown to regulate 3T3-L1 pre-adipocyte
differentiation (Hirata et al., 2011), this enzyme regulates adi-
pogenesis. Pre-adipocytes secrete basic fibroblast growth factor
(bFGF/FGF-2), involved in promoting vascular endothelial cell
growth, levels of which are increased with obesity (Bell et al.,
2006; Sun et al., 2011). Basic fibroblast growth factor is involved in
recruiting monocytes and neutrophils under chronic inflamma-
tory conditions, it acts synergistically with TNF-α and IFN-γ and
in the absence of these cytokines bFGF could not induce leukocytes
recruitment (Zittermann and Issekutz, 2006).
Pre-adipocyte factor-1 (Pref-1) is a transmembrane protein
expressed exclusively by pre-adipocytes and inhibits adipogen-
esis (Chung et al., 2006; O’Connell et al., 2011). Pref-1 levels
are increased in metabolically unhealthy WAT (O’Connell et al.,
2011) and levels correlate with ATM number. The capacity of
pre-adipocytes to undergo adipogenesis is a critical factor in obe-
sity and IR. Adipogenic potential is impeded with age and by
various cytokines, via the transcription factors CCAAT/enhancer
binding protein (C/EBP)1α (Karagiannides et al., 2001) and per-
oxisome proliferator-activated receptors (PPAR)-γ (Hotta et al.,
1999). Reduced capacity for de novo adipogenesis, coupled with
increased FFA storage demand in obesity may account for the
switch from hyperplastic to hypertrophic WAT, which in turn has
negative implications in terms of impeding FFA storage capacity
and leakage.
ADIPOSE TISSUE MACROPHAGES
Adipose tissue macrophages can be classified based on their surface
marker expression and/or their chemokine and cytokine secretion
profile. ATM number and phenotype is altered in genetic and diet
induced obesity. In the obese state there are greater proportions
of classically activated M1 but less M2 macrophages; which would
otherwise play a role in the resolution of inflammation (Lumeng
et al., 2007; Fujisaka et al., 2009). M1 macrophages secrete pro-
inflammatory cytokines TNF-α, IL-1β, and IL-6; whereas alter-
natively activated M2 macrophages secrete anti-inflammatory
cytokines including IL-10 and IL-1 receptor antagonist (RA)
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(Lumeng et al., 2007). The degree of ATM infiltration is associ-
ated with the progression of IR (Osborn and Olefsky, 2012). It
is likely that M1 ATMs originate from monocytes in circulation
rather than originating in the SVF (Calder et al., 2011; Oh et al.,
2012).
The immuno-phenotype of macrophages is highly plastic in
response to their surrounding milieu (Mosser and Edwards, 2008).
As obesity progresses the ATM phenotype switches from anti-
inflammatory M2 to the pro-inflammatory M1 type, through a
dynamic process spanning a spectrum from M1 to M2 states
(Lumeng et al., 2007; Osborn and Olefsky, 2012). ATM cluster
around necrotic adipocytes in arrangements coined crown-like
structures (CLS). M1 ATM infiltration decreases insulin sensi-
tivity as a result of greater TNF-α, IL-1β, and IL-6 secretion,
which induce an insulin resistant environment. FFAs can activate
macrophages in vitro acting through Toll like receptor (TLR)2
and TLR4 to induce MCP-1, IL-6, and IL-1β expression (Nguyen
et al., 2007). FFAs also induce PAI-1 secretion from macrophages
in vitro; however this induction occurred only in the presence
of 3T3-L1 adipocytes in the culture environment, suggesting
FFA’s and adipocyte secretions act synergistically to influence
macrophage secretions (Kishore et al., 2010). ATM infiltration
can be detected after only 1 week of HFD feeding (Lynch et al.,
2012) and increase progressively with time and in proportion to
the degree of obesity. With obesity ATM also take on a foam cell-
like role, accumulating excess lipid (Prieur et al., 2011). Weight
loss is associated with lower ATM number (Kosteli et al., 2010)
however initial rapid weight loss is also accompanied by transient
infiltration of macrophages (Granneman et al., 2005; Sun et al.,
2011).
There is some uncertainty when distinguishing macrophages
from DCs (Geissmann et al., 2010); these cell types overlap in terms
of function and molecular characterization. Both are phagocytic
antigen presenting cells (APC) and also share certain cell surface
markers including CD11c, MHC II, and F4/80. The Immunolog-
ical Genome Project has generated detailed gene expression pro-
files and regulatory pathways that enable discrimination between
macrophages and DCs and additionally to distinguish between
different populations of these cell types (Gautier et al., 2012).
This project shows that there was great diversity between different
macrophage populations but detected only 39 mRNA transcripts
common to all macrophage types but not to DCs.
T CELLS
Adipose tissue macrophages were the first immune cells asso-
ciated with IR, however in terms of WAT infiltration they are
preceded by other immune cells including T cells. Different T
cell subsets are involved in obesity and WAT infiltration. Regu-
latory T cells (Treg) normally constitute 5–20% of the CD4+ T
cell population and play a crucial role in maintaining immune
homeostasis (Feuerer et al., 2009). Treg secrete anti-inflammatory
cytokines, inhibiting macrophage migration, and promoting an
M2 macrophage phenotype (Osborn and Olefsky, 2012). A decline
in Tregs accompanies increasing weight gain in both mouse and
human (Feuerer et al., 2009; Winer et al., 2009a). The Treg depleted
mouse has lower insulin-stimulated insulin receptor tyrosine
phosphorylation in both epididymal fat and liver, accompanied
by reduced AKT phosphorylation (Feuerer et al., 2009). Anti-
inflammatory CD4+ T helper (TH) 2 cells secrete IL-4 and IL-13
(Winer et al., 2009a). Interleukin-4 induces M2 macrophages that
secrete IL-10, which in turn is proposed to have insulin sensitizing
potential.
Pro-inflammatory TH1 cells secrete IFN-γ that drives polar-
ization of pro-inflammatory macrophages, that in turn secrete
IL-1, IL-6, and TNF-α (Winer et al., 2009a). TH1 cells can acti-
vate macrophages (Zhu and Paul, 2008). HFD feeding increased
TH1 cell number thus negating the anti-inflammatory secretions
from Treg and TH2 cells (Winer et al., 2009a). Interleukin-6 in
conjunction with IL-23, TGF-β, and IL-1, drive the proliferation
of CD4+ TH17 cells (Kikly et al., 2006; Brereton et al., 2009).
Activation of ERK in DCs is crucial in driving IL-1β and IL-
23 production that further drive the expansion of TH17 cells
(Brereton et al., 2009). TH17 cells secrete the pro-inflammatory
cytokines IL-17A and IL-17F and also TNF-α, IL-6, GM-CSF,
CXCL1, and CCL20. Winer et al. (2009b) reported an increase
in TH17 cells in the spleens of HFD-fed mice, but TH17 cells
were absent in HFD-fed IL-6−/− mice. HFD-fed Rag1−/− mice
reconstituted with CD4+ T cells had lower weight gain than those
reconstituted with CD8+ T cells, both had similar food intake
(Winer et al., 2009a). The CD4+ T cell recipient mice also had
smaller adipocytes in both subcutaneous and epididymal fat pads.
The infiltration of CD8+ T cells to WAT is an early event in
obesity, whereby obese WAT can activate CD8+ T cells that subse-
quently recruit macrophages (Nishimura et al.,2009; Harford et al.,
2011). The percentage of CD8+CD4− T cells in the SVF fraction
of epididymal fat increased in HFD-fed mice after just 2 weeks.
CD8+CD4− T cell number increased for up to 11 weeks on HFD
while both CD8−CD4+ and Treg numbers decreased over time
(Nishimura et al., 2009). Depletion of CD8+ cells resulted in a sig-
nificant reduction in CD8+CD4− T cells numbers in epididymal
fat pads, and reduced M1 macrophage infiltration; without alter-
ing the M2 fraction in HFD-fed mice. In order to demonstrate
the effects of obese versus lean WAT on CD8+ T cells, epididy-
mal fat pads from chow and HFD-fed mice were co-cultured with
splenic CD8+ T cells; the obese WAT induced T cell prolifera-
tion to a greater extent than the lean WAT (Nishimura et al.,
2009).
Invariant natural killer T (iNKT) cells are a population of innate
T cells present in WAT; obesity is accompanied by a decline in iNKT
cells in WAT (Lynch et al., 2012). This cell type can recognize lipid
antigens on MHC-like glycoprotein CD1 (Brigl and Brenner, 2004;
Lynch et al., 2009b). DCs express CD1 and in vivo may activate
iNKT cells (Exley and Koziel, 2004). There is uncertainty about
naturally occurring ligands recognized by iNKT cells; endogenous
lysosomal glycosphingolipid and isoglobotrihexosylceramide in
addition to bacterial glycosphingolipids are proposed iNKT lig-
ands (Zhou et al., 2004; Kinjo et al., 2005; Lynch et al., 2009b).
iNKT cells are found at a higher frequency in mouse than in
human, however they are particularly present in the human omen-
tum, this region also contains the highest concentration of CD1d+
cells (Lynch et al., 2009b). iNKT cells comprise up to 50% of res-
ident T cells in the liver (Eberl et al., 1999) and in the WAT they
produce TH2 type cytokines. Jα18 deficient mice and CD1d−/−
mice lack iNKT cells, with this absence there is an increase in
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macrophage number in WAT (Lynch et al., 2012). Both show
greater M1 infiltration of WAT following HFD feeding. CD1d−/−
mice have decreased adiponectin and increased leptin levels in
WAT and plasma (Schipper et al., 2012). Lean mice deficient
in iNKT develop an insulin resistant phenotype in the absence
of WAT inflammation (Schipper et al., 2012). These lean mice
also displayed adipocyte hypertrophy but there was no change in
epididymal fat pad weight relative to wild-type mice.
DENDRITIC CELLS
Dendritic cells are considered the principal APC of the immune
system and are crucial for initiating a T cell response (Sallusto and
Lanzavecchia, 1994). They process phagocytosed particles and use
peptide information from these to present to T cells via MHC
class I and class II molecules. DCs are the only cell type that
can induce naïve T cell differentiation (Sallusto and Lanzavecchia,
1994; Bhattacharya et al., 2011). Mature DCs secrete cytokines that
influence different cell responses, e.g., naïve T cells to TH1, -2, -
17, Tregs and therefore DCs link innate and adaptive arms of the
immune system. TH1 cell induction follows pro-inflammatory IL-
12p70 secretion by DCs (McGuirk et al., 2005); TH1 cells then
produce IFN-γ and can prevent the development of Treg cells
(DePaolo et al., 2011). Additionally IFN-γ feeds back to DCs
ensuring the continued production of IL-12p70. Inactivation of
MEK1/2 in the MAPK pathway leads to a reduction in IL-1β
and IL-23 production but does not result in diminished IL-12p70
production.
Adipose and bone marrow DC number increases following
HFD feeding in mice (Reynolds et al., 2012). Further studies have
shown HFD feeding also results in DC infiltration of the liver in
addition to the WAT (Stefanovic-Racic et al., 2012). DCs present
in the liver of obese mice have increased CD86 expression, suggest-
ing that the obese environment promotes DC maturation. Addi-
tionally Flt3−/− mice, lacking DCs, showed reduced macrophage
infiltration of liver and WAT. DCs isolated from the SVF of lean
and obese mice contained different population subsets (Bertola
et al., 2012); CDllchigh/F4/80low DCs from obese mice induced
the differentiation of TH17 cells that produced high levels of IL-
17, whereas CDllchigh/F4/80neg DCs induced both TH1 and TH17
cells that produced low levels of their respective cytokines IFN-
γ and IL-17. In lean mice CDllchigh/F4/80neg DCs only induced
TH1 cells and CDllchigh/F4/80low DCs initiated a weak TH17 cell
expansion.
Zhong et al. (2013) investigated the role of dipeptidyl
peptidase-4 (DDP4/CD26) in human DCs in relation to T cell acti-
vation. Dipeptidyl peptidase-4 was first identified as an enzyme
involved in the degradation of glucagon-like peptide (GLP)-1
(Yazbeck et al., 2009). Dipeptidyl peptidase-4 expression was inves-
tigated in human peripheral blood and the SVF fraction from the
omentum of healthy lean subjects (Zhong et al., 2013). Expression
of DPP4 was greater on DCs and macrophages from the SVF frac-
tion than those from the peripheral blood. Dipeptidyl peptidase-4
expressing macrophages were measured from visceral adipose tis-
sue (VAT) of obese subjects and levels were higher than observed
in lean controls; both HFD-fed mice and ob/ob mice also showed
increase DPP4 expression in WAT, and on DCs and macrophages
(Zhong et al., 2013).
NATURAL KILLER CELLS
Natural killer (NK) cells represent the first line of immune defense
(Shi et al., 2000). They produce IFN-γ and can drive TH1 cell
expansion (Yadav et al., 2011), they also produce IL-17 (Cua and
Tato, 2010). Subjects deemed obese yet metabolically healthy had a
greater number of CD8+ cells and NK cells than their “unhealthy”
counterparts, but both groups had fewer circulating NK cells than
lean subjects (Lynch et al., 2009a). NK cells differed in phenotype
between the two groups of obese patients; there was increased
expression of inhibitory markers such as NKB1 and CD158b in
the unhealthy group. Adipokines can influence NK cells and lep-
tin was shown to have an inhibitory effect on NK cells in lean
but not obese subjects while adiponectin enhanced NK activity in
obese subjects (O’Shea et al., 2010).
EOSINOPHILS
Eosinophils are classically associated with allergy but are also asso-
ciated with M2 macrophages. Eosinophils are present in the WAT
of mice and produce IL-4 thus act to replenish M2 macrophages;
they account for 4–5% of SVF cells in the WAT (Wu et al., 2011).
TH2 cell IL-4 production may complement eosinophil IL-4 secre-
tion, or indeed make it redundant (Maizels and Allen, 2011). A
decline in eosinophil numbers has been reported in HFD-fed mice
(Wu et al., 2011) and in the absence of eosinophils M2 macrophage
numbers become diminished.
THE LIVER AND SKELETAL MUSCLE ARE CRITICAL ORGANS
ADVERSELY AFFECTED IN OBESITY-INDUCED INSULIN
RESISTANCE
LIVER
Obesity induces morphological and metabolic alterations in other
peripheral tissues including the liver and skeletal muscle. NAFLD
is a complex metabolic disorder transpiring to be one of the most
prevalent liver conditions in the western world (Flegal et al., 2002;
Utzschneider and Kahn, 2006). NAFLD is strongly linked with
obesity, IR, and T2D (Seppala-Lindroos et al., 2002; Adams et al.,
2005). This condition represents multiple pathogenic states from
steatosis to steatohepatitis which can progress to cirrhosis and
liver failure (Farrell and Larter, 2006). In an obese state the liver
exhibits selective IR; the inhibitory effect of insulin on hepatic
gluconeogenesis is interrupted while its action on de novo lipoge-
nesis is enhanced, resulting in chronic hyperglycemia and hyper-
triglyceridemia (Schwarz et al., 2003; Brown and Goldstein, 2008).
The mechanisms responsible for hepatic IR are controversial and
causality has been attributed to several factors.
The “portal hypothesis” suggests enhanced visceral tissue lipol-
ysis, resultant from obesity-induced IR, exacerbates FFA influx
into the liver via the portal vein, contributing to hepatic steatosis
(Bjorntorp, 1990; Berraondo and Martínez, 2000; Utzschneider
and Kahn, 2006). This increase in hepatic FFA may induce hepatic
IR by promoting protein kinase C (PKC)δ translocation from
the cytosol to the membrane, leading to impaired IRS-associated
phosphatidylinositol (PI)3-kinase activity (Lam et al., 2002). Addi-
tionally elevated WAT derived pro-inflammatory cytokine secre-
tion including TNF-α and reduced adiponectin secretion have also
been implicated in hepatic IR (Berg et al., 2001). Alternatively
excessive TAG accumulation within the liver has been implicated in
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hepatic IR (Utzschneider and Kahn, 2006). Patients with NAFLD
display elevated de novo lipogenesis, which reflects the inability
for insulin to impede lipogenesis (Donnelly et al., 2005). NAFLD
associated hyperinsulinemia can stimulate lipogenic transcription
factor sterol receptor binding protein (SREBP)-1c, and inhibit fork
head transcription factor Foxa2 activity, promoting enhanced FA
synthesis and reduced β-oxidation (Wolfrum et al., 2004; Tamura
and Shimomura, 2005; Gonzalez-Baro et al., 2007). Furthermore,
HFD-fed mice have elevated hepatocyte ceramide secretion (Boon
et al., 2013), this secretion profile is linked to plasma ceramide lev-
els suggesting that the liver is the principal producer of circulating
ceramide.
The liver has a large population of resident macrophages or
Kupffer cells (KC) (Neyrinck et al.,2009). NAFLD is linked with the
inflammatory activation of KCs (Odegaard et al., 2008). Increased
adiposity activates KC,without altering total KC number (Cai et al.,
2005). Activation of KC is associated with hepatic IR (Neyrinck
et al., 2009; Lanthier et al., 2010) and the production of inflam-
matory mediators including TNF-α and reactive oxygen species
(ROS). Similar to ATM, KC present immense plasticity and can
alter between a pro-inflammatory M1 and anti-inflammatory M2
phenotype, in response to their specific environment (Gordon,
2003). Ablation of PPAR-δ, an important FA sensor in hematopoi-
etic cells, polarized KC to an M1 activation state augmenting
HFD-induced hepatic steatosis through a reduction in hepatic
β-oxidation (Odegaard et al., 2008). HFD fed mice depleted of
KCs, have decreased lipogenic gene expression and suppression of
hepatic glucose 6-phosphatase (G6Pase), a crucial gene involved
in gluconeogenesis (Neyrinck et al., 2009). The G protein-coupled
receptor (GPCR) GPR105 is involved in additional macrophage
infiltration of the liver and the ensuing inflammatory and insulin
resistant state (Xu et al., 2012).
SKELETAL MUSCLE
Skeletal muscle is the main target organ for glucose uptake in the
body, responsible for 80% of glucose disposal in man (Lorenzo
et al., 2008; DeFronzo and Tripathy, 2009). Glycogen synthesis is
the principal pathway for glucose disposal in both normal and T2D
subjects (Shulman et al., 1990). Defective glycogen synthesis has a
causative role in IR and T2D (Shulman, 2000). Insulin stimulation
in T2D does not increase glucose-6-phosphate, an intermediary
metabolite of glucose transport and glycogen synthesis. This sug-
gests that T2D is associated with either decreased glucose transport
activity or decreased hexokinase II activity. Further investigation
elucidated that glucose transport is the rate-controlling step in
insulin-stimulated glycogen synthesis (Cline et al., 1999).
Increased circulating FFAs and dysregulation of intramyocel-
lular FA metabolism can result in a ∼50% decrease in insulin-
stimulated glycogen synthesis in muscle (Roden et al., 1996). This
is a consequence of reduced glucose-transport activity and defec-
tive PI3K activity (Dresner et al., 1999; Petersen and Shulman,
2002). In vivo infusion of a lipid emulsion in rats resulted in an
increase in intracellular C18:2 CoA and DAG in skeletal muscle
(Yu et al., 2002). Additionally reduced tyrosine phosphorylation
of IRS-1 and reduced IRS-1 associated PI3K activity followed lipid
infusion; this coincided with increased PKCθ activation. Com-
bined these changes result in decreased insulin-stimulated glucose
transport activity. Circulating ceramides are increased with T2D,
in particular elevated LDL-ceramide is associated with IR (Boon
et al., 2013). Infusion of LDL-ceramide into lean mice resulted
in reduced glucose disposal in skeletal muscle and decreased
phosphorylation of AKT (Boon et al., 2013). In skeletal muscle,
IKKβ signaling increased coincident with increased expression of
NF-κB target genes TNF-α, IL-6, and IL-1β. LDL-ceramide also
decreased insulin-stimulated glucose uptake through decreased
GLUT4 translocation.
Interleukin-6 levels are elevated in obesity, likely due to
greater WAT IL-6 secretion; and are associated with IR and T2D
risk (Spranger et al., 2003; Pedersen and Febbraio, 2008). The
functional role and consequence of IL-6 in skeletal muscle is
highly complex and potentially counterintuitive. In its role as a
myokine, IL-6 expression is enhanced in contracting skeletal mus-
cle and released after exercise, when insulin sensitivity is enhanced
(Ostrowski et al., 1998; Steensberg et al., 2000). Skeletal mus-
cle metabolism is enhanced by IL-6, increasing AMP-activated
protein kinase (AMPK) α2 activity, FA oxidation, and glucose
uptake (Kelly et al., 2009). Interleukin-6 signaling is abnormal in
obese and T2D subjects muscle precursor cells. There is reduced
skeletal muscle IL-6 receptor expression in obesity and abnormal
STAT3/suppressor of cytokine signaling 3 (SOCS3) signaling, and
attenuated IL-6 induced AMPKα2 activation with T2D (Scheele
et al., 2012).
Hong et al. (2009) investigated IL-10 action in skeletal muscle
glucose homeostasis; using a transgenic mouse model with mus-
cle specific overexpression of IL-10. Following HFD feeding, IL-10
over-expressing mice had improved insulin sensitivity relative to
HFD-fed control mice; additionally increased tyrosine phosphory-
lation of IRS-1 was demonstrated. There was reduced macrophage
infiltration of skeletal muscle in the HFD transgenic mice and a
corresponding reduction in IL-6 and TNF-α secretion in the mus-
cle. TNF-α expression has been shown to be increased in muscle
biopsies from IR subjects (Saghizadeh et al., 1996).
Insulin-independent glucose transport in skeletal muscle
occurs following AMPK activation (Fujii et al., 2006). Leptin
increases fatty oxidation and decreases fat storage in muscle via
AMPK activation. HFD fed mice show decreased leptin-stimulated
AMPK activation (Martin et al., 2006), due to abrogated acetyl-
CoA carboxylase (ACC) activity downstream of the AMPK path-
way. SOCS3, a regulator of leptin, is elevated in the skeletal
muscle of HFD-fed mice (Yang et al., 2012). Overexpression of
SOCS3 impairs leptin-stimulated AMPK activation, reduced tyro-
sine phosphorylation of IRS-1, PI-3-kinase activity, and AKT
phosphorylation (Yang et al., 2012).
White adipose tissue derivatives, either FA or cytokine/inflammatory
derived have a plethora of adverse and synergistic effects on hepatic
and skeletal metabolism, that further augment the impact of
dysregulated WAT metabolism in obesity.
INFLAMMATORY MEDIATORS INVOLVED IN
OBESITY-INDUCED INSULIN RESISTANCE
Metabolic dysregulation has been attributed to numerous pro-
inflammatory cytokines secreted by the altered immune cell milieu
of obese WAT, including IL-1, TNF-α, MIF, and IL-6, all of which
have been documented in disrupting insulin signaling.
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INTERLEUKIN-1 FAMILY
The IL-1 superfamily includes IL-1α, IL-1β, IL-1RA, IL-18, IL-33,
and IL-37 (Dinarello, 2009; Akdis et al., 2011). Interleukin-1 is a
multifunctional pro-inflammatory cytokine, produced by numer-
ous innate immune cells including monocytes/macrophage and
DCs (Garcia et al., 2006; Tilg and Moschen, 2008). Interleukin-
1α and IL-1β mediate their actions through the IL-1 receptor
1(IL-1R1) and potently induce the production of inflammatory
cytokines including IL-6. Conversely IL-1α and IL-1β differ in
their maturation and secretion, IL-1α is secreted in a biologically
active state while IL-1β activation is dependent on the cleavage of
pro-IL-1β to mature IL-1β by caspase-1 (Dinarello et al., 2010).
Interleukin-1β disrupts adipogenesis in human and murine cell
models (Lagathu et al., 2006). IL-1 signaling cascade involves the
activation of NF-κB and JNK MAPK pathways (Stylianou and Sak-
latvala, 1998). In contrast, anti-inflammatory IL-1RA binds to the
IL-1R1 and blocks signaling events due to its lack of an essential
IL-1R accessory protein (Tack et al., 2012). In recent years the full
importance of IL-1 signaling in obesity, adipocyte dysfunction,
and IR has been recognized.
Increased circulating IL-1β concentrations are associated with
greater risk of developing T2D (Spranger et al., 2003). Obese
VAT expresses more IL-1β and IL-1R1 (Juge-Aubry et al., 2003).
Interleukin-1α impairs insulin-stimulated tyrosine phosphoryla-
tion of IRS-1 in 3T3-L1-adipocytes (He et al., 2006). Furthermore
IL-1β inhibited insulin-stimulated glucose uptake into 3T3-L1-
adipocytes, an effect proposed to be mediated via IL-1β induced
ERK activation (Jager et al., 2007). Correspondingly lack of IL-1R1
protects mice from HFD-induced glucose intolerance (De Roos
et al., 2009; McGillicuddy et al., 2011). Treatment of HFD-fed
mice with IL-1RA ameliorated glucose intolerance and protected
against obesity-induced pancreatic β-cell destruction (Sauter et al.,
2008). However a certain element of controversy still surrounds IL-
1 regarding its function in vivo. Interleukin-1RA−/− mice exhibit
a lean phenotype concomitant with enhanced energy expenditure
and improved insulin sensitivity (Matsuki et al., 2003; Isoda et al.,
2005). On the other hand IL-1R1−/− mice develop mature onset
obesity with reduced glucose homeostasis (Garcia et al., 2006).
Together these studies highlight the pathological significance of IL-
1 to obesity associated metabolic dysregulation but also highlight
the complexity of this signaling molecule.
PROCESSING ACTIVE IL-1β VIA NLRP3 INFLAMMASOME
The processing and activation of IL-1β in vivo comprises a multi-
faceted network of events wherein two individual stress response
signals are required to “prime” and “activate” IL-1β. Activation of
TLR4 via stress signals such as lipopolysaccharide (LPS) or satu-
rated fatty acids (SFA) delivers the first “hit” necessary for produc-
tion of pro-IL-1β (Wen et al., 2011). The subsequent processing of
pro-IL-1β to mature biologically active IL-1β is dependent on the
NOD like Receptor (NLRP)3-caspase 1 inflammasome complex
(Mills and Dunne, 2009). The NLRP3 inflammasome is a multi-
molecular complex recently demonstrated as central to obesity-
induced IR. This complex is comprised of NLRP3, the adap-
tor molecule-apoptosis-associated speck-like protein containing a
CARD and pro-caspase-1. Assembly of the NLRP3 inflammasome
is mediated through a diverse range of endogenous and exogenous
stressors including FFAs, glucose, adenosine triphosphate (ATP),
uric acid, and ROS (Netea et al., 2009). Activation of the inflam-
masome induces caspase-1 activity required for cleaving pro-IL-1β
to mature IL-1β. Indeed the importance of the NLRP3 inflam-
masome and caspase-1 activity in obesity-induced IR has been
recently highlighted. Vandanmagsar et al. confirmed that weight
loss through calorie restriction or exercise diminished NLRP3
expression in WAT. Moreover NLRP3−/− mice were protected
from the adverse metabolic effects elicited by HFD; demonstrated
by improved glucose homeostasis, greater insulin-induced pAKT
activity in VAT, subcutaneous adipose tissue (SAT), liver and mus-
cle. Interestingly, similar to IL-1R1 deficient mice, lack of NLRP3
did not alter the ATM M1/M2 ratio (Vandanmagsar et al., 2011).
Stienstra et al. illustrated that caspase-1 expression was amplified
during adipocyte differentiation and this increase was associated
with reduced insulin sensitivity. Lack of caspase-1 or NLRP3
increased adipogenesis and lipid accumulation in adipocytes. Fur-
thermore, lack of caspase-1 prevented HFD-induced IR (Stienstra
et al., 2010). These studies indicate that the inflammasome which
modulates IL-1 activation/mediated inflammation is a critical
regulator of inflammation and WAT function.
TUMOR-NECROSIS FACTOR-α
Tumor-necrosis factor-α is a potent pro-inflammatory cytokine,
primarily secreted from monocytes and macrophages, via the
activation of MAPK and NF-κB signaling pathways, resulting in
the release of other inflammatory cytokines such as IL-1β and
IL-6 (Chen and Goeddel, 2002; De Luca and Olefsky, 2006). It
was the first inflammatory mediator linked with obesity-induced
IR (Hotamisligil et al., 1993). Chronic treatment of 3T3-L1
adipocytes with TNF-α activated intracellular IKKβ and reduced
tyrosine phosphorylation of IRS-1, ultimately leading to impaired
insulin action. Obese rodents administered TNF-α neutralizing
antibody exhibited reduced hyperinsulinemia (Hotamisligil et al.,
1994). Whole body deletion of TNF-α or its corresponding recep-
tor TNF receptor 1 (TNFR1) gene partially protects mice from
obesity-induced IR (Uysal et al., 1997). Several studies have shown
TNF-α can also indirectly alter insulin sensitivity. The treatment
of 3T3-L1 adipocytes with TNF-α increased lipolysis but also
down-regulated adipogenic genes; PPAR-γ and C/EBP. Further-
more TNF-α activated NF-κB suppressed genes involved in lipid
uptake and storage (Ruan et al., 2002). Obese human subjects
exhibit elevated circulating levels of TNF-α (Hotamisligil et al.,
1995; Kern et al., 1995). However the benefits of anti-TNF therapy
in T2D are limited.
INTERLEUKIN-10
Interleukin-10 is an anti-inflammatory cytokine produced by
monocytes, M2 ATMs, DCs, T cells, and B cells. It was ini-
tially discovered through its role in preventing the production
of TH1 cytokines in mice (Moore et al., 2001). It signals via
the IL-10 receptor (IL-10R) to activate the JAK/STAT pathway
and exerts immuno-suppressive effects by blocking IκK activity
(Schottelius et al., 1999) or by inducing tyrosine phosphorylation
of STAT-3 (Lumeng et al., 2007). Interleukin-10 may play a pro-
tective role in obesity-induced metabolic dysregulation and IR.
Interleukin-10 levels are attenuated in T2D (Van Exel et al., 2002)
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and weight loss enhances WAT IL-10 expression coincident with
reduced pro-inflammatory gene expression (Cancello et al., 2005).
Lumeng et al. have demonstrated elevated IL-10 expression in
ATM and within the SVF of lean WAT compared with obese WAT.
Interleukin-10 reduced MCP-1 secretion from 3T3-L1-adiopcytes.
Moreover pre-treatment of 3T3-L1-adiopcytes with IL-10 blocked
the insulin-desensitizing effects of TNF-α and enhanced insulin-
stimulated glucose transport (Lumeng et al., 2007). Interleukin-10
is associated with many immune cells and production by TH cells
initiates a feedback loop that can limit the effector functions of
macrophages and DCs. It can also drive differentiation of IL-10
secreting Treg cells (Saraiva and O’Garra, 2010). Interleukin-10
can inhibit the production of MHC class II and co-stimulatory
molecule expression in DCs and macrophages, it can also prevent
the production of cytokines from CD4+ T cells (Joss et al., 2000;
Couper et al., 2008).
Other studies have challenged the protective effects of IL-10 in
obesity-induced IR. Deletion of hematopoietic cell derived IL-10
did not exacerbate WAT or liver inflammation in response to HFD.
However IL-10 expression was markedly up-regulated in WAT
and liver in these mice compared to wild type (WT) mice, sug-
gesting induction of a compensatory mechanism (Kowalski et al.,
2011). Therefore further in vivo studies are required to evaluate
the significance of IL-10 in obesity-induced IR.
INTERLEUKIN-6
Interleukin-6 is secreted by WAT, skeletal muscle, and the liver
(Fasshauer et al., 2003; Weisberg et al., 2003; Wieckowska et al.,
2008). Interleukin-6 signals via the JAK/STAT and MAPK path-
ways (Heinrich et al., 2003). WAT and plasma IL-6 expression is
correlated with BMI (Vozarova et al., 2001) and up-regulated by
insulin and TNF-α; it negatively impacts on insulin signaling pro-
moting serine phosphorylation of IRS-1 (Fasshauer et al., 2003;
Ruge et al., 2009). Interleukin-6 may promote dysregulation of FA
metabolism in WAT as it enhances mesenchymal stem cell pro-
liferation, maintaining the cells in an undifferentiated state and
inhibiting adipogenesis (Pricola et al., 2009). Increased hepatic IL-
6 levels are also associated with steatohepatitis and plasma IL-6
levels (Wieckowska et al., 2008). Additionally IL-6 was recently
shown to stimulate insulin secretion via enhanced GLP-1 expres-
sion in pancreatic cells (Ellingsgaard et al., 2011). This suggests
that obesity-induced IL-6 secretion may reflect a mechanism to
increase insulin production in the obese IR state. However, while
elevated IL-6 secretion from WAT and the liver is unfavorable, the
opposite is true for skeletal muscle. Physical inactivity decreases
insulin sensitivity, it is also associated with reduced skeletal muscle
IL-6 expression and secretion (Pedersen and Febbraio, 2012). Fur-
thermore the increase in plasma IL-6 levels that result from exercise
are followed by increased IL-1RA and IL-10 levels, and exercise
induced IL-6 is thought to result from glycogen/MAPK activation
rather than through NF-κB (Pedersen, 2011); thus highlighting
the pleiotropic role of IL-6.
MACROPHAGE MIGRATION INHIBITORY FACTOR
Several studies suggest an association between MIF and obesity-
induced IR (Vozarova et al., 2002; Dandona et al., 2004; Ghanim
et al., 2004; Church et al., 2005). Macrophage migration inhibitory
factor has a prominent role in macrophage biology, it promotes
secretion of TNF-α, IL-6, IL-1β, and inhibits IL-10, propagat-
ing a pro-inflammatory response (Calandra et al., 1994; Baugh
and Bucala, 2002; Calandra and Roger, 2003; Lue et al., 2007).
Moreover MIF can sustain activated macrophage life span by
thwarting p53-dependent apoptosis (Mitchell et al., 2002) and
induce chemotaxis via CXCR2 and CXCR4 in macrophages and
T cells respectively (Bernhagen et al., 2007). Plasma MIF con-
centrations and PBMC MIF mRNA are positively associated
with BMI, FFA concentration, impaired glucose tolerance (IGT),
and IR (Vozarova et al., 2002; Skurk et al., 2005). Obese SAT
explants demonstrate increased MIF secretion, and expression
is increased with adipocyte size IR (Skurk et al., 2005; Koska
et al., 2009). Weight loss and treatment with the anti-diabetic
drug metformin reduces plasma MIF concentrations coincident
with improved pancreatic β-cell function (Dandona et al., 2004;
Church et al., 2005). More recently a causal role for MIF in IR
was emphasized using an atherosclerotic mouse model which
lacked functional MIF (LDLR−/−MIF−/−). This model displayed
less local WAT inflammation, reduced MAC3+ macrophage infil-
tration, with enhanced WAT and systemic insulin sensitivity
(Verschuren et al., 2009). In addition deletion of MIF reduced
monocyte adhesion, macrophage lesion content, and atheroscle-
rotic lesion size (Verschuren et al., 2009). Unpublished work
within our group implicates MIF as a critical inflammatory reg-
ulator in the pathogenesis of HFD-induced IR with an essential
role in HFD-associated ATM recruitment. It has since emerged
that lack of MIF signaling results in an age-dependent impair-
ment of glucose homeostasis in mice fed a chow diet (Serre-
Beinier et al., 2010), highlighting the intricacy of this mole-
cule and lack of true clarity in terms of its functional role in
obesity-induced IR.
ADIPONECTIN
Adiponectin is a 30-kDa secretory hormone produced predomi-
nantly by adipocytes, expression, and secretion are elevated dur-
ing adipocyte differentiation (Carbone et al., 2012). Reduced
adiponectin levels such that accompany obesity, result in IGT
due to reduced insulin sensitivity (Arita et al., 1999; Fantuzzi,
2005). There are three major isoforms of adiponectin; low mole-
cular weight (LMW), formed from three adiponectin monomers,
middle-molecular weight (MMW) which is an octomer, and high-
molecular weight (HMW) consisting of 12 or more monomers
(Magkos and Sidossis, 2007). HMW adiponectin is the most bio-
logically active form and best reflective of the reduction in total
adiponectin levels associated with obesity (Almeda-Valdes et al.,
2010). Indeed HMW-adiponectin levels have been identified as an
independent risk factor for IR (Aso et al., 2006; Hara et al., 2006;
Almeda-Valdes et al., 2010).
Adiponectin can enhance FA oxidation and improve insulin
sensitivity (Carbone et al., 2012); suppressing gluconeogenesis in
the liver thus reducing circulating glucose levels, also increasing
glucose uptake in the muscle by enhanced GLUT4 expression.
In the liver, adiponectin stimulates glucose and FA oxidation
through activation of the AMPK pathway and reduces lipogen-
esis by minimizing SREBP-1c expression (Utzschneider and Kahn,
2006).
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In addition to its insulin sensitizing role, adiponectin is typi-
cally anti-inflammatory. Adiponectin can suppress the production
of TNF-α and IFN-γ and it is speculated to be a negative regulator
of T cells (Scherer et al., 1995; Carbone et al., 2012). Tsang et al.
(2011) demonstrated that chronic adiponectin treatment in DCs
decreased the expression of the co-stimulatory molecules CD80
and CD86, MHC II, and also IL-12. Additionally adiponectin
treated DCs had altered T cell interactions with reduced pro-
liferation of TH1 cells and Treg cell induction. Thus targeting
adiponectin signaling pathways may be promising in the treatment
of metabolic diseases.
CYTOKINE SYNERGY TO AUGMENT OBESITY-INDUCED
INSULIN RESISTANCE
Given the complexity of pro-inflammatory signaling, it is highly
probable that a combination of stimuli rather than a single entity
would elicit greater accountability for the inflammation-IR para-
digm. Certainly it is known that IL-1, TNF-α, and TLR4 converge
at the inhibitor of NF-κB kinase complex (IκB kinase) (Verstrepen
et al., 2008). McGillicuddy et al. (2011) emphasized the potent
synergistic capabilities IL-1β and TNF-α in macrophages and
WAT. Intriguingly this study showed that lack of IL-1 signaling
altered the immunogenic phenotype of ATM, with reduced IL-6
and TNF-α secretion, but without altered ATM number. Cor-
respondingly AT inflammation was reduced concomitant with
enhanced insulin-stimulated pAKT expression. This study also
showed that adipocytes exposed to IL-1β and TNF-α induced
greater activation of NF-κB, with significant amplification of IL-
6 secretion compared with either cytokine alone. Furthermore
abrogation of IL-1R1 in bone marrow macrophages ablates these
synergistic abilities. To investigate this phenomenon in a more
physiological relevant setting, WAT explants from WT and IL-
1R1−/− mice were cultured in the presence of IL-1β and TNF-α
ex vivo, loss of synergy was again observed in IL-1R1−/− WAT.
Another important inflammatory regulator that offers potential
involvement in IL-1, TNF-α, and TLR4 signaling is MIF (Finu-
cane et al., 2012). Endogenous MIF regulates innate immunity
via upregulation of TLR4, IL-1R1, and p55 tumor-necrosis fac-
tor receptor (TNFR) expression (Roger et al., 2001; Toh et al.,
2006). MIF−/− macrophages were shown to be hypo-responsive
to LPS and failed to secrete TNF-α and IL-6 due to profound sup-
pression of IKKβ/NF-κB activity (Roger et al., 2001). Macrophage
migration inhibitory factor deficiency suppressed IL-1 and TNF-α
induced MAPK activity and cell proliferation in mouse fibrob-
lasts. Reconstitution of an upstream MAPK or MIF reversed this
suppression (Toh et al., 2006). Furthermore, treatment of 3T3-
L1 adipocytes with TNF-α induced MIF secretion, suggesting that
TNF-α may regulate MIF production during obesity (Hirokawa
et al., 1997, 1998). In vivo MIF deficient mice were hypo-responsive
to TNF-α and exhibited euglycemia, indicating MIF is required for
successful TNF-α action. Additionally 3T3-L1 adipocytes exposed
to exogenous MIF demonstrated impaired insulin-stimulated glu-
cose uptake and insulin receptor signal transduction. Similarly in
response to inflammatory stress MIF−/− mice exhibit a marked
improvement in WAT glucose uptake compared to control mice
(Atsumi et al., 2007).
ACTIVATION AND PROPAGATION OF INFLAMMATION AND
INSULIN RESISTANCE
The NF-κB and JNK MAPK pathways link obesity, inflammation,
and IR, summarized in Figure 4 (Hirosumi et al., 2002; Shoelson
et al., 2003). But despite intense scrutiny, an intricate question
persistently evades resolution, what instigates and consequentially
propagates this inflammation? See Figure 5. Reduced ability of
WAT to adequately store excess fat and an increased hypoxic
environment have been proposed as two potential contributors.
Hypoxia represents a metabolic stressor relevant to obese WAT, this
local hypoxia may be partially attributed to an insufficient blood
supply reaching the expanding organ (Kabon et al., 2004; Hosogai
et al., 2007). Hypoxia-inducible factor-1 (HIF)-1 is a transcription
factor with an oxygen regulated α subunit (HIF-1 α) (Bruning
et al., 2011; Shin et al., 2012); tissue inflammation is associated
with regions of hypoxia, and HIF signaling is also linked to NF-κB
activation (Ye et al., 2007; Bruning et al., 2012). WAT hypoxia
correlated with reduced expression of adiponectin in a HFD-
fed mouse model. Moreover, hypoxic conditions augment WAT
derived cytokines including leptin and IL-6 (Sun et al., 2011). Con-
versely, weight loss improves adipose oxygenation and increases
adiponectin expression. HIF-1α is a critical regulator of cellular
hypoxic responses and is rapidly degraded under normoxic con-
ditions. HIF-1α activity increases early in obesity. Overexpression
of HIF-1α initiates WAT fibrosis, accompanied by increased local
inflammation. Halberg et al. (2009) suggest that hypoxia induced
WAT fibrosis may be responsible for initiating WAT inflamma-
tion during obesity. A HIF-1α antisense oligonucleotide (ASO)
suppressed Hif-1α gene expression in the liver and WAT of HFD-
fed mice (Shin et al., 2012), and resulted in weight loss without a
change in food intake or activity levels. In vitro analysis of hypoxia
in tumor cell lines showed that resveratrol (Zhang et al., 2005;
Park et al., 2007) and two isoforms of conjugated linoleic acid
(CLA) c9,t 11- and t 10,c12-CLA (Yamasaki et al., 2012) can pro-
mote HIF-1α protein degradation; suggesting that the hypoxia
related inflammatory response in WAT is nutrient sensitive.
Decreased WAT expandability may result in lipid spillover,
elevating circulating FFAs resulting in enhanced ectopic lipid
accumulation in peripheral tissues (Khan et al., 2009; Prieur
et al., 2011). Long-chain (LC) SFA can serve as a ligand to the
innate immune receptor TLR4 (Shi et al., 2006). Indeed, expos-
ing macrophages and adipocytes to varying concentrations of
palmitate, the most abundant circulating SFA in obesity, elic-
its a TLR4 dependent pro-inflammatory response characterized
by increased NF-κB and JNK activation with resultant enhanced
TNF-α cytokine secretion in vitro. Furthermore TLR4−/− mice
administered an acute lipid infusion maintained glucose home-
ostasis (Shi et al., 2006). HFD-fed mice lacking TLR4 had attenu-
ated IR, increased energy expenditure and improved WAT inflam-
mation (Shi et al.,2006; Tsukumo et al.,2007). While bone-marrow
transplant studies indicate that TLR4 in the hematopoietic sys-
tem opposed to the non-hematopoietic system may be responsible
for TLR4 mediated IR during HFD wherein TLR4 chimeric mice
exhibit reduced hyperinsulinemia, hepatic, and WAT IR (Saberi
et al., 2009). Despite abundant reports signifying that TLR4 ame-
liorates WAT inflammation, the effect on ATM accumulation has
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FIGURE 4 | Cross-talk between insulin and inflammatory signaling
pathways. Inflammatory signaling pathways activated by SFA or by
pro-inflammatory cytokines IL-1β, IL-6, and TNF-α initiate a cascade of events
that promote the release of further inflammatory mediators. These signaling
events converge at the NF-κB and MAPK pathways, resulting in the
translocation of transcription factors to the nucleus, transcriptional activation,
and cytokine production. The inflammasome is activated through a two-hit
process; with obesity the first hit occurs when TLR4 is activated by SFAs and
this results in pro-IL-1β production, ATP or ceramides then provide the second
hit. The NLRP3 inflammasome acts on pro-caspase-1 causing the release of
caspase-1; caspase-1 then acts upon pro-IL-1β cleaving this precursor to the
active IL-1β form. Insulin signaling promotes glucose uptake by promoting the
translocation of GLUT4 to the cell surface plasma membrane. Inflammatory
signaling pathways can alter the phosphorylation status of IRS-1. IRS-1 is
crucial in the insulin signaling pathway, tyrosine phosphorylation is associated
with an insulin sensitive state. IKKβ and JNK can promote serine
phosphorylation of IRS-1 and this phosphorylation state is linked to insulin
resistance and reduced glucose uptake.
remained unclear. In this regards Orr et al. (2012) demonstrated
TLR4 deficiency did not alter ATM number but promoted ATM
toward an M2 anti-inflammatory phenotype.
Dietary FA have been shown to interact with DCs and alter
cell function (Loscher et al., 2005; Weatherill et al., 2005; Zeyda
et al., 2005). Saturated fatty acid drives DC maturation through
interaction with TLR4. Bone marrow derived dendritic cells
(BMDCs) isolated from HFD-fed mice are skewed toward a pro-
inflammatory phenotype with increased secretion of IL-1β, IL-
12p70, and TNF-α in response to LPS (Reynolds et al., 2012).
Interleukin-1R1, TLR4, caspase-1, and NLRP3 mRNA expression
also increases in BMDCs from HFD-fed mice; additionally cell
surface TLR4 expression was also significantly increased. Polyun-
saturated fatty acids (PUFA) have an opposing effect on DC
function and can suppress IL-12p70 production while boosting IL-
10 release, thus driving a Treg rather than a TH1 response (Loscher
et al., 2005; Weatherill et al., 2005). PUFA largely exert an effect
via changes in gene expression causing activation of transcription
factors (Bouwens et al., 2010).
Specific FAs as well as some eicosanoids have been shown to
bind to receptors of the PPAR family of transcription factors,
including the PPAR-α, PPAR-β/δ, and PPAR-γ isoforms (Forman
et al., 1997; Delerive et al., 1999). PPAR act as a hub between
inflammation and insulin sensitivity, via physical interactions with
NF-κB and IκBα (Ricote et al., 1998; Delerive et al., 2002); antago-
nizing inflammation and promoting insulin signaling. Activation
of PPAR-γ is associated with the upregulation of IRS proteins
(Hammarstedt and Smith, 2003; Seto-Young et al., 2007); addi-
tionally the thiazolidinedione class of drugs which act as PPAR-
agonists, promote tyrosine phosphorylation of IRS-1 in both
in vivo and in vitro models (Jiang et al., 2002, 2004). Neverthe-
less it is impossible to adequately address PPAR functionality in
obesity within the current review and this topic was reviewed
very comprehensively elsewhere (Stienstra et al., 2007; Varga et al.,
2011).
Ectopic accumulation of excessive palmitate-derived lipid plays
an antagonistic role in insulin signaling (Gill and Sattar, 2009).
Ceramides in particular are postulated to be a critical factor
connecting disproportionate lipid accretion, inflammation, and
impaired insulin sensitivity (Summers, 2006). Indeed activation
of a TLR4 inflammatory response via SFA is essential for SFA
induced ceramide biosynthesis (Holland et al., 2011). Ceramides
comprise of sphingosine bound to a FA and serve as both struc-
tural and signaling molecules (Gill and Sattar, 2009). Ceramides
are generated by condensation of palmitoyl-CoA and serine via
the rate-limiting enzymatic reaction mediated by serine palmi-
toyltransferase (Mathias et al., 1998; Summers, 2006). Impor-
tantly pro-inflammatory cytokine such as IL-1β amplify ceramide
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FIGURE 5 | Activation and propagation of inflammation and
insulin resistance in obese adipose tissue. Adipocyte
hypertrophy results in elevated circulation of FFAs (A) and
increased secretion of adipokines (B). These in turn result in
immune cell infiltration and the activation of pro-inflammatory
signaling pathways, driving further infiltration and the polarization of
adipose tissue macrophages and T cells toward a pro-inflammatory
phenotype. This environment then drives further adipokine
secretions (C) and hampers adipogenesis, resulting in greater
numbers of pre-adipocytes that in turn secrete pro-inflammatory
mediators. Together these events lead to defective insulin signaling
and ultimately to an insulin resistant state.
biosynthesis by upregulating serine palmitoyltransferase (Sum-
mers, 2006). Haus et al. (2009) ascribed a pathogenic associ-
ation between total plasma ceramide and its subspecies C18:0,
C20:0, C24:1, C24:0 concentrations and the degree of IR in obese
T2D patients. Elevated circulating TNF-α levels were positively
correlated with increased C18:1 and C18:0 ceramide subspecies.
Culturing C2C12 myoblasts in the presence of palmitate
induced de novo ceramide accumulation, disrupting insulin-
stimulated pAKT activation. Inhibiting ceramide accumulation
negated the detrimental effects on insulin signaling. How-
ever, whether ceramides induced an inflammatory response in
myoblasts was not assessed in this study (Chavez et al., 2003).
Further, Holland et al. demonstrated enhanced ceramide accumu-
lation in the soleus muscle in response to lard oil infusion but not
soy oil infusion, a source of PUFAs. Inhibiting ceramide infusion
using serine palmitoyltransferase inhibitors prevented ceramide
induced IR. Additionally lard oil evoked a significant increase in
circulating pro-inflammatory IL-6 and TNF-α (Holland et al.,
2011). Most recently ceramides were identified as an effective
second “hit” required for NLRP3 inflammasome activation in
macrophages. Furthermore, ceramides evoked NLRP3 dependent
caspase-1 activation in obese WAT explants, an event that was
lost in NLRP3−/− WAT (Vandanmagsar et al., 2011). Despite sig-
nificant evidence highlighting the importance of ceramides in
inflammation and IR the clinical importance of these findings is
yet to be fully deciphered. A subsequent study reported that palmi-
tate was a potential second signal required for NLRP3 activation,
inducing IL-1β production from macrophages. Both NLRP3 and
the inflammasome adaptor ASC (apoptotic speck-like protein con-
taining a CARD, known also as Pycard) deficiency ameliorated
obesity-induced IR in mice (Wen et al., 2011).
INSULIN RESISTANCE AS A PROTECTIVE MECHANISM
It has been hypothesized that the induction of IR is perhaps a pro-
tective response. Insulin resistance could potentially act to protect
cells from stress and damage through the exclusion of glucose
from cells that are heavily lipid loaded; thus reducing the chance
of lipotoxic damage (Unger, 2003). In vivo and in vitro rat stud-
ies indicate that glucose toxicity occurs when cells are exposed
to a chronic hyperglycemic state (Rossetti et al., 1990), and this
may induce or aggravate IR (Baron et al., 1995). Impaired GLUT
4 translocation in response to the metabolite glucosamine has
been implicated in the induction of IR (Baron et al., 1995). Roden
et al. (1996) determined through lipid infusion studies in healthy
volunteers, that FFA’s inhibit glucose transport. It has since been
demonstrated that prolonged FFA exposure but not short-term
exposure, interrupts glucose uptake (Hawkins et al., 1997). Alter-
natively IR may be induced partly in response to oxidative stress.
Oxidative stress describes a biological state that develops following
increased ROS production or reduced ROS clearance (Azzi, 2007).
ROS production increases in response to increased macronutrient
consumption (Codoñer-Franch et al., 2011). Excessive nutrient
intake is linked to an increase in superoxide (O2•−) generation
by mitochondria (Tiganis, 2011). Mitochondria produce most
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of the cell’s energy, and in this capacity take up the majority of
intracellular oxygen (Finkel and Holbrook, 2000). Cell signaling
pathways are activated in response to increasing oxidative stress;
these pathways include MAPK, NF-κB, and the PI3K-AKT path-
way (Finkel and Holbrook, 2000). Hoehn et al. (2009) propose
that IR is linked to mitochondrial O2•− and that O2•− acts
as a nutrient sensor, which regulates nutrient intake under con-
ditions of overnutrition. This group reports that mitochondrial
O2•− is upstream of IR in skeletal muscle and AT; overexpression
of mitochondrial superoxide dismutase (MnSOD) enzymes, with
anti-oxidant action, in in vitro and in vivo rodent models signif-
icantly improved insulin sensitivity. Additionally, findings from
caloric restriction (CR) studies show reduced oxidative damage
(Sohal et al., 1994; Sohal and Weindruch, 1996; Masoro, 2000;
Zainal et al., 2000). Sirtuin 1 (SIRT1) a member of the sirtuin
family of proteins, may mediate the effect of CR by influenc-
ing PPAR-γ, PGC1-α, and FOXO (Han et al., 2010). SIRT1 has
previously been shown to improve insulin sensitivity in in vitro
and in vivo mouse studies (Moynihan et al., 2005; Sun et al.,
2007).
METABOLICALLY HEALTHY OBESE
Interestingly 20–30% of obese adults do not express the adverse
metabolic phenotype typically associated with obesity (Alam et al.,
2012). Individuals considered metabolically healthy but obese
(MHO) have high levels of insulin sensitivity but may not display
symptoms of hypertension, dyslipidemia, or chronic inflamma-
tion (Karelis et al., 2005; Stefan et al., 2008; Succurro et al., 2008).
MHO individuals have significantly smaller omental adipocytes
than metabolically unhealthy individuals (O’Connell et al., 2010).
This finding correlates with the degree of IR and hepatic steato-
sis within the obese groups. Interestingly this study demonstrated
that BMI was not associated with adipocyte size nor did it predict
general metabolic health or fatty liver disease, in a group of adults
with a median BMI of 48 kg/m2. Brochu et al. (2001) demon-
strated in a group of obese postmenopausal women, that MHO
individuals had lower levels of VAT; and that these women had
been obese for longer than the metabolically unhealthy group.
Additionally the MHO group was shown to have lower plasma
TAG levels and higher high-density lipoprotein (HDL) cholesterol
concentrations. In a study of obese males and females, fitness levels
were higher in the MHO group (Ortega et al., 2013). Conversely
an individual may be considered metabolically obese but normal
weight (MONW) (Ruderman et al., 1981). Adult female subjects
determined to be MONW tend to have a similar BMI to their
metabolically healthy counterparts but have a higher percentage
body fat, lower fat-free mass, and lower physical activity energy
expenditure, and are considered to be less aerobically fit (Conus
et al., 2004). Female MONW subjects were shown to have increased
plasma cholesterol and reduced insulin sensitivity but showed no
change in ghrelin, leptin, or adiponectin levels (Conus et al., 2004).
MONW subjects also have increased TAG and FFA levels. Low-
HDL cholesterol levels have been noted in male MONW subjects
when compared with healthy non-obese subjects (Succurro et al.,
2008; Lee et al., 2011).
TARGETING NUTRIENT-SENSITIVE INFLAMMATORY
PATHWAYS TO TREAT INSULIN RESISTANCE
There is no doubt that weight loss can improve the inflammatory
phenotype and insulin sensitivity (Kopp et al., 2005; Kováciková
et al., 2011). However, maintenance of weight loss is difficult to
achieve and weight regain frequently occurs (Gage, 2012). Thus
there is a vital need to identify alternative nutritional interven-
tions that may antagonize inflammation, independent of weight
loss. As proof of concept from a pharmaceutical perspective, drugs
that (1) interfere with the TLR4/IKK/NF-kB axis, (2) target PPAR-
γ, or (3) target pro-inflammatory cytokines, have demonstrated
promise with respect to treating IR despite obesity. Salicylate,
an inhibitor of IKK has been shown to reverse hyperglycemia,
hyperinsulinemia, and dyslipidemia in obese rodents by sensitiz-
ing insulin signaling (Yuan et al., 2001). Anakinra, an IL-1 RA,
was shown to improve glycemia and beta-cell secretory function
in patients with T2D (Malozowski et al., 2007). Small molecule
MIF antagonist CPSI-1306 treatment in a mouse model with
streptozotocin (STZ)-induced T2D, resulted in reduced circu-
lating IL-6 and TNF-α levels and reduced blood glucose levels
(Sanchez-Zamora et al., 2010). Nevertheless, long-term pharma-
cological immuno-suppressive interventions that attenuate IR,
may not be ideal in terms of immunosurveillance and long-term
health (Kung and Henry, 2012; Bortolini et al., 2013). Alter-
natively, anti-inflammatory nutritional interventions may have
potential. Albeit producing a more subtle effect, several nutrients
have now emerged as potentially insulin sensitizing, affecting the
same molecular targets as established pharmaceutical approaches.
Perhaps the most extensively researched in relation to their
immunomodulating effects are dietary FA which are known to
interact with several inflammatory pathways (Hotamisligil and
Erbay, 2008). The effect of FAs on these pathways depends on
the degree of FA saturation (Bradley et al., 2008). Within this
context, eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), two LC n− 3 PUFAs have emerged as anti-inflammatory
nutrients that exert their effects through a number of biological
mechanisms. Opposingly, SFA activate TLR4 and increase NF-κB
transcriptional activity. EPA and DHA may mitigate this response
(Bradley et al., 2008; Reynolds et al., 2012) by reducing nuclear
p65 expression and increasing cytoplasmic IκBα expression, and
DHA may act as a more potent NF-κB inhibitor than EPA (Wel-
don et al., 2007). Xue et al. (2012) suggested that this effect is
partially mediated via AMPK/SIRT1 activation as DHA does not
fully deacetylate p65 in SIRT1 knockdown macrophages. Fur-
thermore pre-treatment of macrophages with DHA promotes an
anti-inflammatory phenotype, with reduced IL-6 and increased
IL-10 expression; which when co-cultured with adipocytes attenu-
ates the characteristic IR phenotype (Oliver et al., 2012). Therefore
the anti-inflammatory effects observed due to DHA pre-treatment
were translated into improved insulin sensitivity in adipocytes
(Oliver et al., 2012).
The GPCR GPR120 that is highly expressed in both adipocytes
and macrophages, plays a pivotal role in LC n− 3 PUFA medi-
ated inhibition of inflammation and IR (Oh et al., 2010). Both
EPA and DHA bind to the GPR120 receptor to inhibit NF-κB and
www.frontiersin.org May 2013 | Volume 4 | Article 52 | 13
McArdle et al. Mechanisms of obesity-induced inflammation and insulin resistance
JNK via reduced TAK1 phosphorylation (Oh et al., 2010). Further-
more it was demonstrated that LC n− 3 PUFA supplementation
increased insulin sensitivity in WT but not in GPR120−/− mice
(Oh et al., 2010). Additionally LC n− 3 PUFA may exert their
anti-inflammatory effect by enhancing adiponectin secretion from
human adipocytes, an effect that is elicited at least partially, via
PPAR-γ (Tishinsky et al., 2011). These results are consistent with
in vivo work that demonstrated feeding mice a fish oil enriched diet
increases plasma adiponectin, and this was completely blocked by
the PPAR-γ antagonist BADGE (Neschen et al., 2006).
Long-chain n− 3 PUFA may increase β-oxidation in WAT and
cultured adipocytes (Guo et al., 2005; Flachs et al., 2011), poten-
tially via activation of the AMPK regulatory pathway (Lorente-
Cebrián et al., 2009; Figueras et al., 2011). This metabolic switch
could increase the mitochondrial content of adipocytes, resulting
in reduced accumulation of toxic FA derivatives and improved
insulin sensitivity (Kopecky et al., 2009). Furthermore, LC n− 3
PUFA competitively inhibit the conversion of arachidonic acid
(AA) to pro-inflammatory eicosanoids such as prostaglandin E2
and leukotriene B4. Increased intake of LC n− 3 PUFA pro-
mote the incorporation of EPA into membrane phospholipids
at the expense of AA, thereby increasing production of EPA-
derived anti-inflammatory eicosanoids, such as prostaglandin E3
and leukotriene B5 (Lottenberg et al., 2012). Whilst the poten-
tial benefits of LC n− 3 PUFA supplementation on inflammatory
pathways is clear in vitro, it is difficult to ascertain a consistent
effect in man (Kabir et al., 2007; Tierney et al., 2011). Inconsisten-
cies in human data are reflective of dose variability between studies,
duration of supplementation, and the population studied (Calder
et al., 2011). Genetic variability between individuals likely influ-
ences responsiveness to an intervention (Calder et al., 2011). Single
nucleotide polymorphisms (SNPs) can influence responsiveness,
MetS patients that are minor allele carriers of an adiponectin SNP
have reduced IR following reduced SFA intake (Ferguson et al.,
2010). A second study showed that common genetic variants of the
complement component 3 (C3) locus conferred an increased risk
of MetS, and that PUFA intake may modulate these genetic influ-
ences (Phillips et al., 2009a). Therefore gene-nutrient interactions
may play an important role in regards to responsiveness to inter-
ventions, a personalized nutrition approach may be considered in
order to determine an ideal dietary intervention.
There is growing evidence, albeit highly controversial, in rela-
tion to the immunomodulating potential of vitamin D. Fol-
lowing in vitro induced inflammation, 1,25-dihydroxyvitamin
D up-regulates IκBα in macrophages through increased mRNA
stability and decreased IκBα phosphorylation, thus reducing
NF-κB activity (Cohen-Lahav et al., 2006). Furthermore, 1,25-
dihydroxyvitamin D suppresses TLR2 and TLR4 expression in
human monocytes (Sadeghi et al., 2006). Du et al. (2009) demon-
strated vitamin D3 pre-treatment of monocytes from T2D patients
and controls resulted in similar TLR2 and TLR4 expression, NF-κB
p65 phosphorylation state, and IL-1β and TNF-α expression in the
two groups. Nevertheless human data is inconsistent, intervention
studies have shown little or no effect of vitamin D supplemen-
tation on inflammatory or metabolic markers related to insulin
sensitivity (Gulseth et al., 2010; O’Sullivan et al., 2011). Further-
more cross-sectional data showed that serum vitamin D status
bore no relationship with insulin action or secretion in subjects
with the MetS (Gulseth et al., 2010).
Vitamin C and vitamin E have been proposed to improve
insulin sensitivity through anti-oxidant and anti-inflammatory
mechanisms. As an anti-oxidant, ascorbic acid down-regulates
ROS that otherwise would lead to activation of NF-κB (Nathan,
2003). Moreover, after oxidation to dehydroascorbic acid, vitamin
C has been shown to directly inhibit IKKα, IKKβ, and p38 MAPK
activity (Cárcamo et al., 2004). Vitamin C has also been shown
to inhibit nitric oxide (NO) production and decrease insulin-
induced MCP-1 and apelin secretion in an adipocyte-macrophage
co-culture (Garcia-Diaz et al., 2011). Similarly, the insulin sensi-
tizing effect of lycopene, a carotenoid pigment found in tomatoes
involves inhibition of NF-κB, NO, and IL-6, and suppresses the
activation of a number of MAP kinases (Feng et al., 2010). Phos-
phorylation of the MAP kinases ERK, p-38, and JNK, were shown
to be ameliorated by lycopene (Kim et al., 2004). In WAT, pro-
inflammatory cytokine and chemokine expression were reduced
by lycopene treatment (Gouranton et al., 2011). A recent study
conducted in young overweight adults showed that daily supple-
mentation with one glass of tomato juice reduced TNF-α, IL-6,
and IL-8 after 20 days (Ghavipour et al., 2012). Another study
in overweight men demonstrated a decrease in systemic levels
of serum amyloid A after 12 weeks of lycopene supplementation
(McEneny et al., 2012). However Thies et al. (2012) demonstrated
that following a 12-week treatment on a tomato-rich diet, inflam-
matory markers such as highly sensitive CRP (hsCRP) and IL-6,
and HOMA-IR, remained unchanged.
Polyphenols, particularly flavonoids are gaining increas-
ing attention for their anti-inflammatory effect. Resveratrol, a
polyphenol that naturally occurs in grapes (Dong, 2003) was
shown to inhibit pre-adipocyte proliferation, adipogenic differ-
entiation, and de novo lipogenesis in a SIRT1-dependent man-
ner in SGBS (Simpson–Golabi–Behmel syndrome) adipocytes
(Fischer-Posovszky et al., 2010). Interestingly in humans it has
been demonstrated that resveratrol treatment can improve the
metabolic phenotype of healthy obese men, by reducing blood glu-
cose and insulin levels and reducing plasma inflammatory markers
(Timmers et al., 2011). Nevertheless it must be acknowledged that
there have been other resveratrol interventions which have had
little effect (Poulsen et al., 2012; Yoshino et al., 2012). Poulsen et
al. demonstrated that resveratrol failed to improve endogenous
glucose production and turnover or improve inflammatory and
metabolic biomarkers in obese but otherwise healthy men. Addi-
tionally plasma lipids and insulin sensitivity did not improve;
neither was there a change in molecular targets such as AMPK
or SIRT1 in non-obese women treated with resveratrol (Yoshino
et al., 2012).
Epigallocatechin gallate (EGCG) present in green tea, has been
implicated in inhibiting resistin gene expression in adipocytes
(Liu et al., 2006) and was shown to decrease ERK phosphory-
lation. Yang et al. (2001) demonstrated EGCG also inhibits IKK. A
recent investigation of quercetin, demonstrated that this flavonoid,
found predominantly in capers, apples, and grapes, attenuated
TNF-α-induced NF-κB activity and subsequent expression of
inflammatory genes in primary human adipocytes (Chuang et al.,
2010).
Frontiers in Endocrinology | Diabetes May 2013 | Volume 4 | Article 52 | 14
McArdle et al. Mechanisms of obesity-induced inflammation and insulin resistance
Curcumin which is the yellow pigment found in the spice
turmeric inhibits LPS-induced secretion of TNF-α and IL-1β
in vitro (Chan, 1995). Curcumin also completely inhibits TNF-α-
induced activation of NF-κB and other inflammatory agents such
as phorbol esters (Singh and Aggarwal, 1995). Salicylic acid, the
basic component of aspirin is present in fruits, vegetables, herbs,
and spices (Duthie and Wood, 2011). Relatively low concentra-
tions of salicylic acid have been shown to inhibit cyclooxygenase
(COX)-2 in vitro (Wu et al., 1991; Xu et al., 1999; Hare et al., 2003)
and suppress the transcriptional activation of pro-inflammatory
genes such as iNOS (Duthie and Wood, 2011). However, salicylate
concentrations sufficient to inhibit NF-κB activation are unlikely
to be achieved through diet, limiting the therapeutic potential of
salicylic acid in its natural form (Duthie and Wood, 2011; Wood
et al., 2011).
Much of the research to date has examined the effect of indi-
vidual nutrients on inflammation however recent evidence sug-
gests that a combination of nutrients may offer an enhanced
immunomodulating effect. Bakker et al. (2010) demonstrated
that supplementing overweight men with a combination of nutri-
ents, with known anti-inflammatory properties, increased plasma
adiponectin by 7% over a 5-week period, independent of weight
loss. Additionally, large-scale profiling of genes, proteins, and
metabolites showed that the intervention could influence inflam-
mation, oxidative stress, and metabolism. Anti-inflammatory
IL-10Rα and SOCS3 expression were up-regulated in WAT in
response to the intervention (Bakker et al., 2010). This study high-
lights the potential efficacy of nutritional interventions that target
multiple signaling pathways to treat IR in obese individuals.
Despite convincing evidence from in vitro and animal studies
to support the therapeutic potential of several nutrients within the
context of obesity-induced inflammation and IR, results from clin-
ical studies are not entirely consistent. Even high dose nutritional
supplementation often fails to elicit an anti-inflammatory effect
(Blok et al., 1997; Jellema et al., 2004; Pot et al., 2009). Much of the
discrepancy observed may stem from the examination of supra-
physiological doses in in vitro studies (Calder et al., 2011). Taken
together a cocktail of nutrients may be more beneficial in ame-
liorating the inflammatory phenotype observed in a number of
pathologies. There is no doubt that there is potential for nutritional
anti-inflammatory agents to improve IR within the obese pheno-
type. Nevertheless demonstrating efficacy is confounded by defin-
ing an effective dose of individual dietary elements and/or defin-
ing potential synergies between anti-inflammatory nutrients/food
components. Determining effective doses may be facilitated by
the development of specific functional foods, enriched with the
active agents. There is strong evidence that some individuals with
the MetS who have a pro-inflammatory status due to their geno-
type and/or inflammatory phenotype may be more susceptible to
the pro-inflammatory effect of dietary SFA (Phillips et al., 2009b,
2013). Furthermore their pro-inflammatory genotype/phenotype
may determine potential responsiveness to an intervention. There-
fore there may be a difference in efficacy between sub-cohorts of
the obese population to anti-inflammatory interventions; and a
dual approach in terms of removing SFA and augmenting nutri-
tional anti-inflammatory agents may be required to achieve the
desired effect to attenuate IR.
CONCLUSION
Inflammation is a critical mediator in obesity-induced IR. WAT
expansion and the influx of immune cells initiate a cascade of
inflammatory events that directly contribute to defective insulin
signaling and glucose uptake, resulting in systemic IR. The mech-
anisms driving the pathogenic environment of obese WAT are
complex and not fully elucidated; evidence implicates that a com-
bination of events converge, and escalate the pro-inflammatory
state. Research suggests that nutritional anti-inflammatory inter-
ventions may attenuate IR, independent of weight loss. However,
results from human studies so far remain inconsistent. Moving
forward, greater consideration should be given to designing nutri-
tional interventions that (1) target multiple signaling pathways and
(2) take account of genetic polymorphisms in order to improve
efficacy.
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